Mylan

988 articles with Mylan

• 

  Pfizer Offers $345 Million to Settle Out of EpiPen Pricing Lawsuit

  7/16/2021

  In 2016, Mylan’s EpiPen became the flashpoint of drug pricing outrage when it became widely reported the life-saving drug had increased more than 400% in price over a period of seven years.
• 

  Difficult Decisions, Strategic Streamlining Lead to Workforce Reductions

  12/15/2020

  Mergers and acquisitions are a well-known fact in the life sciences industry, and anyone working within the sector knows to expect them at any time.
• 

  Top 16 Highest-Paid Women CEOs in the Biopharma Industry

  12/10/2020

  Female leaders in the biopharma industry may further promote diversity and inclusion at the workplace and serve as role models for young female professionals. Here is a list of 16 of the highest-paid female CEOs in biopharma.

• Viatris Inc. Launches as a New Kind of Healthcare Company, Positioned to Meet the World's Evolving Healthcare Needs

  11/16/2020

  Combination of Mylan and Pfizer's Upjohn Business Focused on Access and Improved Patient Health

• Mylan Announces Third Quarter 2020 Financial Results and Looks Ahead to the Launch of Viatris Inc.

  11/6/2020

   Mylan N.V. (NASDAQ: MYL) today announced its financial results for the three and nine months ended September 30, 2020. Third Quarter 2020 Financial Highlights Total revenues of $2.97 billion , a slight increase on an actual basis and a slight decrease on a constant currency basis, compared to the

• 

  FTC Clears Merger between Mylan and Pfizer's Upjohn Business

  11/4/2020

  Pfizer and Mylan are less than two weeks away from finalizing the merger of the generic drugmaker with Pfizer’s Upjohn business unit.

• Mylan Announces Appointment of Experienced Pharmaceutical Executive Bill Szablewski as Head of Capital Markets for Viatris

  11/2/2020

  Mylan N.V. (NASDAQ: MYL) today announced that Bill Szablewski , CFA, has joined the company as Head of Capital Markets, in a new leadership role working closely with senior leadership. He will be serving in that same capacity for VIATRIS TM  ("Viatris"). At Viatris, Szablewski will be responsible for

• Mylan and Pfizer Receive Clearance from the U.S. Federal Trade Commission for Proposed Combination of Mylan and Upjohn

  10/30/2020

  Mylan N.V. and Pfizer Inc. announced that the U.S. Federal Trade Commission accepted a proposed consent order, which concludes the FTC’s review of the proposed combination of Mylan and Pfizer’s Upjohn Business.

• Mylan and Development Partner, Synthon, Win Significant European Patent Office Ruling Related to Copaxone® 40mg/mL

  9/15/2020

   Mylan N.V. (NASDAQ: MYL) today announced that the Technical Board of Appeal of the European Patent Office (EPO) has held that Yeda Research and Development Compa

• Mylan and Pfizer Receive European Commission Approval for Proposed Combination of Mylan and Upjohn

  9/15/2020

  The Companies Have Also Received Approvals in Australia and New Zealand; Combination on Track to Close in Fourth Quarter 2020

• Mylan to Acquire Aspen's Thrombosis Business in Europe

  9/8/2020

  Mylan N.V. announced an agreement to acquire the related intellectual property and commercialization rights of Aspen Pharmacare Holdings Limited's thrombosis business in Europe for EUR 641.9 million, subject to customary closing conditions and European regulatory clearances.

• 

  Mylan Acquires Aspen's European Thrombosis Portfolio for $757.3 Million

  9/8/2020

  The portfolio is made up of well-established injectable coagulants sold in Europe under various brand names, including Arixtra, Fraxiparine, Mon-Embolex and Orgaran.

• Mylan and Biocon Biologics Announce Launch of Semglee™ (insulin glargine injection) in the U.S. to Expand Access for Patients Living with Diabetes

  8/31/2020

  Semglee available in vial and pen presentations at a 65% discounted list price, the lowest available for a long-acting insulin glargine on the market

• Mylan Brings Critical Access to the Multiple Sclerosis Community by Launching a More Affordable Treatment Option Through a First Generic to Tecfidera®

  8/19/2020

  Mylan N.V. announced the launch of the first FDA-approved therapeutically equivalent, substitutable generic of Biogen's Tecfidera® capsules.

• 

  Mylan Wins Approval for First Generic to Biogen's MS Drug Tecfidera

  8/19/2020

  This morning, Mylan announced the launch of its new generic offering, dimethyl fumarate delayed-release capsules for the treatment of relapsing forms of multiple sclerosis.

• Mylan Reports Strong Second Quarter and First Half 2020 Results and Updates 2020 Guidance

  8/6/2020

  Mylan N.V. announced its financial results for the three and six months ended June 30, 2020.

• Mylan to Release Second Quarter 2020 Financial Results on Aug. 6, 2020

  7/22/2020

  Global pharmaceutical company Mylan N.V.  (NASDAQ: MYL) today announced that it will release its second quarter 2020 financial results on Thurs., Aug. 6 , before the open of the U.S. financial markets. The company also will host a webcast at 10:30 a.m. ET on Aug. 6 to discuss the results. The briefing

• Mylan and Fujifilm Kyowa Kirin Biologics Announce U.S. FDA Approval of Hulio® (adalimumab-fkjp)

  7/9/2020

  Mylan N.V. and Fujifilm Kyowa Kirin Biologics Co., Ltd. announced that the U.S. Food and Drug Administration has approved Hulio®, a biosimilar to AbbVie's Humira®, for the treatment of rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, adult Crohn's disease, ulcerative colitis and plaque psoriasis, in both prefilled syringe and auto-injector presentations.

• Mylan Initiates Voluntary Nationwide Recall of One Lot of Daptomycin for Injection, Due to the Presence of Particulate

  7/7/2020

  Mylan N.V. (NASDAQ: MYL) today announced that its U.S.-based Mylan Institutional LLC business is conducting a voluntary nationwide recall to the consumer level of one lot of Daptomycin for Injection, 500 mg/vial due to the presence of particulate matter found in one single-dose vial manufactured by Mylan Laboratories Limited's Specialty Formulation Facility

• Mylan Secures Regulatory Approval for Remdesivir Lyophilized Powder for Injection 100 mg/vial in India for Restricted Emergency Use in COVID-19 Patients

  7/6/2020

  Mylan N.V. announced that the Drug Controller General of India has approved its remdesivir 100 mg/vial for restricted emergency use in India as part of the DCGI's accelerated approval process to address urgent, unmet needs amid the evolving coronavirus 2019 pandemic.